Jørgensen K A, Ingeberg S
Nephron. 1979;23(5):233-6. doi: 10.1159/000181641.
In 20 chronic uremic patients on maintenance hemodialysis, who were not taking any medication known to affect platelet function, the following investigations were carried out: platelet count, fibrin/fibrinogen degradation products, fibrinogen and plasminogen concentration, platelet adhesiveness, clot retraction and platelet aggregation induced by ADP, ristocetin, fibrinogen, collagen and epinephrine. The only significant abnormal result was a decreased clot retraction. We consider many cases of so-called uremic bleeding to be caused by the medication taken and conclude that on well-controlled hemodialysis treatment, bleeding tendency should not be a major problem.
对20名维持性血液透析的慢性尿毒症患者进行了以下检查,这些患者未服用任何已知会影响血小板功能的药物:血小板计数、纤维蛋白/纤维蛋白原降解产物、纤维蛋白原和纤溶酶原浓度、血小板黏附性、血块退缩以及由二磷酸腺苷(ADP)、瑞斯托菌素、纤维蛋白原、胶原和肾上腺素诱导的血小板聚集。唯一显著的异常结果是血块退缩减少。我们认为许多所谓的尿毒症出血病例是由所服用的药物引起的,并得出结论,在控制良好的血液透析治疗中,出血倾向不应是一个主要问题。